Cymbalta's Chronic Pain Woes Continue As Advisory Committee Faces Cancellation
This article was originally published in The Pink Sheet Daily
Executive Summary
Indication would be major expansion of the market for Lilly's SSNRI, but the application has already been withdrawn once.